Korean J Schizophr Res.  2021 Oct;24(2):45-51. 10.16946/kjsr.2021.24.2.45.

Supporting Patients With Schizophrenia in the Era of COVID-19

• Kim SW

• KMID: 2522030
• DOI: http://doi.org/10.16946/kjsr.2021.24.2.45

Abstract

The coronavirus disease 2019 (COVID-19) pandemic has drastically impacted our society and health care system. People with schizophrenia are more vulnerable to this burden of illness and related societal changes. In addition, they are more susceptible to the transmission of COVID-19 and have a significantly higher mortality rate compared to the general population. In a recent study, vaccinated patients with schizophrenia showed a greatly decreased mortality level similar to that of the general population. However, patients with schizophrenia were less likely to be vaccinated. Mental health professionals should provide them with appropriate information on prevention strategies against COVID-19 and vaccination. Long-lasting social distancing and social disconnection can make people with schizophrenia more vulnerable to loneliness and depression. Furthermore, patients with schizophrenia may face challenges continuing psychiatric treatment due to the COVID-19 pandemic. Social support and suitable mental health services using novel technologies should be developed and provided to patients with schizophrenia.

Keyword

COVID-19; Health; Schizophrenia; Social support; Vaccination; 건강; 백신; 사회적 지지; 조현병; 코로나19

Reference

1. Kim M, Park IH, Kang YS, Kim H, Jhon M, Kim JW, et al. Comparison of psychosocial distress in areas with different COVID-19 prevalence in Korea. Front Psychiatry. 2020; 11:593105.

2. Ryu S, Park IH, Kim M, Lee YR, Lee J, Kim H, et al. Network study of responses to unusualness and psychological stress during the COVID-19 outbreak in Korea. PLOS One. 2021; 16:e0246894.

3. Mueller AL, McNamara MS, Sinclair DA. Why does COVID-19 disproportionately affect older people? Aging (Albany NY). 2020; 12:9959–9981.

4. Kim SW, Su KP. Using psychoneuroimmunity against COVID-19. Brain Behav Immun. 2020; 87:4–5.

5. Yao H, Chen JH, Xu YF. Patients with mental health disorders in the COVID-19 epidemic. Lancet Psychiatry. 2020; 7:e21.

6. Xiang YT, Zhao YJ, Liu ZH, Li XH, Zhao N, Cheung T, et al. The COVID-19 outbreak and psychiatric hospitals in China: managing challenges through mental health service reform. Int J Biol Sci. 2020; 16:1741–1744.

7. Kim SW, Park WY, Jhon M, Kim M, Lee JY, Kim SY, et al. Physical health literacy and health-related behaviors in patients with psychosis. Clin Psychopharmacol Neurosci. 2019; 17:279–287.

8. Mazereel V, Van Assche K, Detraux J, De Hert M. COVID-19 vaccination for people with severe mental illness: why, what, and how? Lancet Psychiatry. 2021; 8:444–450.

9. Pinkham AE, Ackerman RA, Depp CA, Harvey PD, Moore RC. COVID-19-related psychological distress and engagement in preventative behaviors among individuals with severe mental illnesses. NPJ Schizophr. 2021; 7:7.

10. Lerner AM, Folkers GK, Fauci AS. Preventing the spread of SARSCoV-2 with masks and other “low-tech” interventions. JAMA. 2020; 324:1935–1936.

11. Jung HR, Park C, Kim M, Jhon M, Kim JW, Ryu S, et al. Factors associated with mask wearing among psychiatric inpatients during the COVID-19 pandemic. Schizophr Res. 2021; 228:235–236.

12. Lee YR, Lee JY, Park IH, Kim M, Jhon M, Kim JW, et al. The relationship among medical usage regarding COVID-19, knowledge about infection, and anxiety: structural model analysis. J Korean Med Sci. 2020; 35:e426.

13. Barlati S, Nibbio G, Vita A. Schizophrenia during the COVID-19 pandemic. Curr Opin Psychiatry. 2021; 34:203–210.

14. Wang Q, Xu R, Volkow ND. Increased risk of COVID-19 infection and mortality in people with mental disorders: analysis from electronic health records in the United States. World Psychiatry. 2021; 20:124–130.

15. Nemani K, Li C, Olfson M, Blessing EM, Razavian N, Chen J, et al. Association of psychiatric disorders with mortality among patients with COVID-19. JAMA Psychiatry. 2021; 78:380–386.

16. Fond G, Nemani K, Etchecopar-Etchart D, Loundou A, Goff DC, Lee SW, et al. Association between mental health disorders and mortality among patients with COVID-19 in 7 countries: a systematic review and meta-analysis. JAMA Psychiatry. 2021; e212274.

17. Vai B, Mazza MG, Delli Colli C, Foiselle M, Allen B, Benedetti F, et al. Mental disorders and risk of COVID-19-related mortality, hospitalisation, and intensive care unit admission: a systematic review and meta-analysis. Lancet Psychiatry. 2021; 8:797–812.

18. Barcella CA, Polcwiartek C, Mohr GH, Hodges G, Søndergaard K, Niels Bang C, et al. Severe mental illness is associated with increased mortality and severe course of COVID-19. Acta Psychiatr Scand. 2021; 144:82–91.

19. Tzur Bitan D, Krieger I, Kridin K, Komantscher D, Scheinman Y, Weinstein O, et al. COVID-19 prevalence and mortality among schizophrenia patients: a large-scale retrospective cohort study. Schizophr Bull. 2021; 47:1211–1217.

20. Tzur Bitan D, Kridin K, Cohen AD, Weinstein O. COVID-19 hospitalisation, mortality, vaccination, and postvaccination trends among people with schizophrenia in Israel: a longitudinal cohort study. Lancet Psychiatry. 2021; 8:901–908.

21. Lee SW, Yang JM, Moon SY, Yoo IK, Ha EK, Kim SY, et al. Association between mental illness and COVID-19 susceptibility and clinical outcomes in South Korea: a nationwide cohort study. Lancet Psychiatry. 2020; 7:1025–1031.

22. Shinn AK, Viron M. Perspectives on the COVID-19 pandemic and individuals with serious mental illness. J Clin Psychiatry. 2020; 81:20com13412.

23. Dickerson F, Schroeder J, Katsafanas E, Khushalani S, Origoni AE, Savage C, et al. Cigarette smoking by patients with serious mental illness, 1999-2016: an increasing disparity. Psychiatr Serv. 2018; 69:147–153.

24. Steiner J, Jacobs R, Panteli B, Brauner M, Schiltz K, Bahn S, et al. Acute schizophrenia is accompanied by reduced T cell and increased B cell immunity. Eur Arch Psychiatry Clin Neurosci. 2010; 260:509–518.

25. Wang AK, Miller BJ. Meta-analysis of cerebrospinal fluid cytokine and tryptophan catabolite alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder, and depression. Schizophr Bull. 2018; 44:75–83.

26. Correll CU, Detraux J, De Lepeleire J, De Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry. 2015; 14:119–136.

27. Villasante-Tezanos AG, Rohde C, Nielsen J, de Leon J. Pneumonia risk: approximately one-third is due to clozapine and two-thirds is due to treatment-resistant schizophrenia. Acta Psychiatr Scand. 2020; 142:66–67.

28. Ferraris A, Szmulewicz AG, Posadas-Martínez ML, Serena MA, Vazquez FJ, Angriman F. The effect of antipsychotic treatment on recurrent venous thromboembolic disease: a cohort study. J Clin Psychiatry. 2019; 80:18m12656.

29. Reilev M, Kristensen KB, Pottegård A, Lund LC, Hallas J, Ernst MT, et al. Characteristics and predictors of hospitalization and death in the first 11 122 cases with a positive RT-PCR test for SARSCoV-2 in Denmark: a nationwide cohort. Int J Epidemiol. 2020; 49:1468–1481.

30. Poblador-Plou B, Carmona-Pírez J, Ioakeim-Skoufa I, Poncel-Falcó A, Bliek-Bueno K, Pozoet MC, et al. Baseline chronic comorbidity and mortality in laboratory-confirmed COVID-19 cases: results from the PRECOVID study in Spain. Int J Environ Res Public Health. 2020; 17:1–14.

31. Nemani K, Conderino S, Marx J, Thorpe LE, Goff DC. Association between antipsychotic use and COVID-19 mortality among people with serious mental illness. JAMA Psychiatry 2021 in press.

32. Perry RJ, Tamborska A, Singh B, Craven B, Marigold R, ArthurFarraj P, et al. Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study. Lancet. 2021; 398:1147–1156.

33. Kim HW, Jenista ER, Wendell DC, Azevedo CF, Campbell MJ, Darty SN, et al. Patients with acute myocarditis following mRNA COVID-19 vaccination. JAMA Cardiol. 2021; e212828.

34. Lorenz RA, Norris MM, Norton LC, Westrick SC. Factors associated with influenza vaccination decisions among patients with mental illness. Int J Psychiatry Med. 2013; 46:1–13.

35. Tzur Bitan D. Patients with schizophrenia are under-vaccinated for COVID-19: a report from Israel. World Psychiatry. 2021; 20:300–301.

36. Miles LW, Williams N, Luthy KE, Eden L. Adult vaccination rates in the mentally ill population: an outpatient improvement project. J Am Psychiatr Nurses Assoc. 2020; 26:172–180.

37. Ettman CK, Abdalla SM, Cohen GH, Sampson L, Vivier PM, Galea S. Prevalence of depression symptoms in US adults before and during the COVID-19 pandemic. JAMA Netw Open. 2020; 3:e2019686.

38. Kim SW, Park IH, Kim M, Park AL, Jhon M, Kim JW, et al. Risk and protective factors of depression in the general population during the COVID-19 epidemic in Korea. BMC Psychiatry. 2021; 21:445.

39. Lee YR, Chung YC, Kim JJ, Kang SH, Lee BJ, Lee SH, et al. Differential pathways of the effects of COVID-19-related stress and fear on depression between patients with schizophrenia and the general population. NPJ Schizophr 2021 in press.

40. Brown E, Gray R, Lo Monaco S, O’Donoghue B, Nelson B, Thompson A, et al. The potential impact of COVID-19 on psychosis: a rapid review of contemporary epidemic and pandemic research. Schizophr Res. 2020; 222:79–87.

41. Muruganandam P, Neelamegam S, Menon V, Alexander J, Chaturvedi SK. COVID-19 and severe mental illness: impact on patients and its relation with their awareness about COVID-19. Psychiatry Res. 2020; 291:113265.

42. Kim SW, Kim JJ, Lee BJ, Yu JC, Lee KY, Won SH, et al. Clinical and psychosocial factors associated with depression in patients with psychosis according to stage of illness. Early Interv Psychiatry. 2020; 14:44–52.

43. Ryu S, Nam HJ, Kim JM, Kim SW. Current and future trends in hospital utilization of patients with schizophrenia in Korea: a time series analysis using National Health Insurance Data. Psychiatry Investig. 2021; 18:795–800.

44. Ryu S, Nam HJ, Baek SH, Jhon M, Kim JM, Kim SW. Decline in hospital visits by patients with schizophrenia early in the COVID-19 outbreak in Korea. Clin Psychopharmacol Neurosci 2021 in press.

45. Zhand N, Joober R. Implications of the COVID-19 pandemic for patients with schizophrenia spectrum disorders: narrative review. BJPsych Open. 2021; 7:e35.

46. Kim SW. Psychosocial intervention for patients with schizophrenia. J Korean Neuropsychitr Assoc. 2018; 57:235–243.

47. Siskind D, Honer WG, Clark S, Correll CU, Hasan A, Howes O, et al. Consensus statement on the use of clozapine during the COVID-19 pandemic. J Psychiatry Neurosci. 2020; 45:222–223.

48. McClay E. Clozapine drug monitoring during COVID-19 for stable adult patients. Available at https://www.sps.nhs.uk/articles/clozapine-drug-monitoring-in-primary-care-during-covid-19-for-stable-patients/. Last updated 15 September 2021.

49. Jeong SH, Kim YS. Challenges in prescribing clozapine in the era of COVID-19: a review focused on immunological implications. Clin Psychopharmacol Neurosci. 2021; 19:411–422.

50. Taipale H, Tanskanen A, Mehtälä J, Vattulainen P, Correll CU, Tiihonen J. 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). World Psychiatry. 2020; 19:61–68.

51. de Leon J, Ruan CJ, Verdoux H, Wang C. Clozapine is strongly associated with the risk of pneumonia and inflammation. Gen Psychiatr. 2020; 33:e100183.

52. Shah RR, Smith RL. Inflammation-induced phenoconversion of polymorphic drug metabolizing enzymes: hypothesis with implications for personalized medicine. Drug Metab Dispos. 2015; 43:400–410.

53. Clark SR, Warren NS, Kim G, Jankowiak D, Schubert KO, Kisely S, et al. Elevated clozapine levels associated with infection: a systematic review. Schizophr Res. 2018; 192:50–56.

54. Ostuzzi G, Papola D, Gastaldon C, Schoretsanitis G, Bertolini F, Amaddeo F, et al. Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations. BMC Med. 2020; 18:466–481.

55. Bishara D, Kalafatis C, Taylor D. Emerging and experimental treatments for COVID-19 and drug interactions with psychotropic agents. Ther Adv Psychopharmacol. 2020; 10:2045125320935306.

56. National Institute for Health Research. Long-acting injectable (LAI) antipsychotics–How to manage patients on long-acting injectable (LAI, or depot) antipsychotics during the COVID-19 pandemic. Available from URL:http://oxfordhealthbrc.nihr.ac.uk/wp-content/uploads/2020/09/4.-Antipsychotic-depots-and-LAIs-COVID-guidance_v6.1-2-column.pdf.

57. Kim SW, Lee BJ, Cheon EJ, Won SH, Jo A, Kim JM, et al. Effectiveness of switching to long-acting injectable aripiprazole in patients with recent-onset and chronic schizophrenia. Clin Psychopharmacol Neurosci 2021 in press.

58. Lee JY, Kim M, Jhon M, Kim JW, Ryu S, Kim JM, et al. Factors associated with a negative emotional response to news media and nationwide emergency text alerts during the COVID-19 outbreak in Korea. Psychiatry Investig. 2021; 18:825–830.

59. Kozloff N, Mulsant BH, Stergiopoulos V, Voineskos AN. The COVID-19 global pandemic: implications for people with schizophrenia and related disorders. Schizophr Bull. 2020; 46:752–757.

60. Kopelovich SL, Turkington D. Remote CBT for psychosis during the COVID-19 pandemic: challenges and opportunities. Community Ment Health J. 2021; 57:30–34.

61. O’Donoghue B, O’Connor K, Thompson A, McGorry P. The need for early intervention for psychosis to persist throughout the COVID-19 pandemic and beyond. Ir J Psychol Med. 2021; 38:214–219.

62. Kim JW, Stewart R, Kang SJ, Jung SI, Kim SW, Kim JM. Telephone based interventions for psychological problems in hospital isolated patients with COVID-19. Clin Psychopharmacol Neurosci. 2020; 18:616–620.

63. Kim SW, Lee GY, Yu HY, Park JH, Lee YS, Kim JW, et al. Development of smartphone application for cognitive behavioral therapy-based case management in patients with schizophrenia. Korean J Schizophr Res. 2016; 19:10–16.

64. Kim SW, Lee GY, Yu HY, Jung EI, Lee JY, Kim SY, et al. Development and feasibility of smartphone application for cognitive behavioural case management of individuals with early psychosis. Early Interv Psychiatry. 2018; 12:1087–1093.

65. Mindlink YouTube channel. Available from URL: https://www.youtube.com/c/마인드링크.

66. Kim SW. 2020 Gwangju Mental Health and Welfare Commission Annual report. Gwangju: Gwangju Mental Health and Welfare Commission;2020.

67. Ryu S, Nam HJ, Jhon M, Lee JY, Kim JM, Kim SW, et al. Trends in suicide deaths before and after the COVID-19 outbreak in Korea. Front Psychiatry 2021 in press.

68. Kim SW, Kim JK, Jhon M, Lee HJ, Kim H, Kim JW, et al. Mindlink: a stigma-free youth-friendly community-based early intervention centre in Korea. Early Interv Psychiatry. 2021; 15:1389–1394.

69. Sham PC, O’Callaghan E, Takei N, Murray GK, Hare EH, Murray RM. Schizophrenia following pre-natal exposure to influenza epidemics between 1939 and 1960. Br J Psychiatry. 1992; 160:461–466.